IGDB.NSCLC Gene View
 
Gene Information        (help)
Gene ERCC1 Ensembl ENSG00000012061 Chromosome 19 Start 50604712 End 50619017
Description DNA excision repair protein ERCC-1 [Source:UniProtKB/Swiss-Prot;Acc:P07992]
GENE RESOURCES :NUCLEOTIDE SEQUENCES :PROTEIN RESOURCES :CLINICAL RESOURCES :REFERENCES :
     HGNC : 3433
     Entrez Gene : 2067
     UCSC : uc002pbv.2
     GeneCards : 3433
     RefSeq : NM_001166049
     CCDS : CCDS12662.1
     Uniprot : P07992
     Interpro : P07992
     OMIM : 126380
     GeneTests : ERCC1
     CGAP : ERCC1
     PMID : 6462228

< Top >


Experimental Evidence        (help)
Expression Sample Number Method Clinical information PubMed Reference
up 80/130(62%) IHCSmoking status(P=0.028)//Histology(P<0.001)//Overall survival(P=0.046) 18036700 Lung Cancer. 2008 Jun;60(3):401-7.

< Top >


Microarray Gene Expression Fold Change Result        (help)
( red: up-regulation / green : down-regulation when p value < 0.01)
( gray background : these probesets might have mapping problems. ref 1, ref 2)
Chip Type Probeset Adenocarcinoma Squamous Cell Carcinoma
Fold Change p value q value Fold Change p value q value
 HG_U95  1878_g_at  0.18  8.40e-3  2.01e-2  0.12  1.39e-1  2.16e-1
 HG_U95  1902_at  0.13  7.90e-2  1.35e-1  0.27  3.11e-3  8.31e-3
 HG_U95  36519_at  0.19  3.98e-3  1.05e-2  0.31  8.60e-4  2.72e-3
 HG_U133A  203719_at  0.03  6.33e-1  6.78e-1  -1.95  6.08e-44  1.25e-43
 HG_U133A  203720_s_at  0.77  4.60e-13  2.13e-12  0.18  4.94e-2  5.26e-2
 HG_U133_Plus2  203719_at  0.40  8.62e-7  3.94e-6  0.65  2.28e-10  1.05e-9
 HG_U133_Plus2  203720_s_at  0.21  6.60e-2  1.07e-1  0.07  5.38e-1  5.96e-1
 HG_U133_Plus2  228131_at  -0.69  6.54e-14  7.79e-13  -0.25  7.06e-3  1.18e-2
 Stanford  22456  0.36  1.78e-1  3.62e-1  0.64  2.55e-2  1.16e-1
 Agilent_HS_21.6K  18206  -0.09  6.05e-2  1.66e-1  -0.00  9.95e-1  9.98e-1

< Top >


Adjuvant Cisplatin/vinorelbine Treatment vs Observation Result        (help) (Pubmed)
( red: up-regulation / green : down-regulation when p value < 0.01)
( gray background color : the mapping problems of probeset. ref_1, ref_2)
Chip Type Probeset Adenocarcinoma Squamous Cell Carcinoma
Fold Change p value q value Fold Change p value q value
 HG_U133A  203719_at  0.40  1.35e-1  7.98e-1  0.04  8.14e-1  1.00e+0
 HG_U133A  203720_s_at  0.88  4.11e-2  7.08e-1  0.07  7.28e-1  1.00e+0

< Top >


Microarray Sample Data        (help)
( The log2 value of tumor samples )
(Average : Average log2 value from Normal Samples.)
        HG_U95 - 1878_g_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U95 - 1902_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U95 - 36519_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133A - 203719_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133A - 203720_s_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133_Plus2 - 203719_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133_Plus2 - 203720_s_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133_Plus2 - 228131_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Stanford - 22456    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Agilent_HS_21.6K - 18206    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

< Top >


Cancer Gene Index        (help)

If 0 entry was found, please remove the search key "lung cancer".
Keyword DiseaseData Statement PubMed Organism
ercc1 epithelial ovarian cancer Clear cell tumors have higher mRNA levels of ERCC1 and XPB than other histological types of epithelial ovarian cancer. 14614013 Human
ercc1 clear cell tumors Clear cell tumors have higher mRNA levels of ERCC1 and XPB than other histological types of epithelial ovarian cancer. 14614013 Human
ercc1 epithelial ovarian cancer PURPOSE: The purpose of the present work was to investigate the relationship between mRNA expression of ERCC1 and XPB, two key genes in the nucleotide excision repair pathway, and clinical resistance of platinum-chemotherapy in histological subtypes of ep 14614013 Human
ercc1 epithelial ovarian cancer EXPERIMENTAL DESIGN: mRNA levels of ERCC1 and XPB in epithelial ovarian cancer specimens from 126 different individuals were assessed using reverse transcription-PCR and followed by Southern hybridization methodology. 14614013 Human
ercc1 clear cell tumors Median values for ERCC1 and XPB mRNAs within clear cell tumors were, on average, >2-fold higher than the other histological tumor types. 14614013 Human
ercc1 tumor Median values for ERCC1 and XPB mRNAs within clear cell tumors were, on average, >2-fold higher than the other histological tumor types. 14614013 Human
ercc1 epithelial ovarian cancer CONCLUSIONS: We conclude that mRNA levels of ERCC1 and XPB tend to be higher in clear cell tumors as opposed to other types of epithelial ovarian cancer. 14614013 Human
ercc1 clear cell tumors CONCLUSIONS: We conclude that mRNA levels of ERCC1 and XPB tend to be higher in clear cell tumors as opposed to other types of epithelial ovarian cancer. 14614013 Human
ercc-1 human tumor Several NER genes in this pathway including XPB, XPD, XPA and ERCC-1 have been implicated in anticancer drug resistance in human tumor cells. 12045463 Human
ercc1 non-small cell lung cancer Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. 12114432 Human
ercc1 ovarian cancers PURPOSE: Overexpression of the excision repair cross-complementing 1 (ERCC1) gene, which is crucial in the repair of cisplatin (CDDP)-DNA adducts, is reported to negatively influence the effectiveness of CDDP-based therapy for gastric and ovarian cancers. 12114432 Human
ercc1 non-small cell lung cancer We investigated whether ERCC1 mRNA expression levels were associated with clinical outcomes after treatment with a combination Gem/CDDP regimen for patients with advanced stage non-small cell lung cancer (NSCLC). 12114432 Human
ercc1 tumors RESULTS: ERCC1 expression was detectable in all tumors. 12114432 Human
ercc1 tumor There were no significant differences in ERCC1 levels by gender, age, performance status, weight loss, or tumor stage. 12114432 Human
ercc1 tumors Median overall survival was significantly longer in patients with low ERCC1 expression tumors (61.6 weeks; 95% confidence interval, 42.4-80.7 weeks) compared to patients with high expression tumors (20.4 weeks, 95% confidence interval, 6.9-33.9 weeks). 12114432 Human
ercc1 squamous cell carcinoma of the head and neck DNA repair gene ERCC1 and ERCC2/XPD polymorphisms and risk of squamous cell carcinoma of the head and neck. 12220217 Human
ercc1 squamous cell carcinoma of the head and neck OBJECTIVE: To determine the effect of the ERCC1 C8092A polymorphism and the ERCC2/XPD G23591A polymorphism on the risk of squamous cell carcinoma of the head and neck (SCCHN). 12220217 Human
ercc1 human tumor Several NER genes in this system including XPA, XPB, ERCC1, and ERCC2 (XPD) have been implicated in anticancer drug resistance in human tumor cells. 12451985 Human
ercc1 non-small cell lung cancer Preliminary findings are that non-small cell lung cancer patients overexpressing ERCC1 mRNA have lower response to cisplatin chemotherapy, while those overexpressing ribonucleotide reductase mRNA have limited benefit from gemcitabine. 12480194 Human
ercc1 non-small-cell lung cancer RESULTS: In the cisplatin-sensitive non-small-cell lung cancer cell line, ERCC1 expression at the mRNA or protein level was not significantly altered in any of the treatment groups. 11163512 Human
ercc1 ovarian cancer In the cisplatin-resistant ovarian cancer cell line, ERCC1 expression was upregulated by TPZ, but not by cisplatin alone. 11163512 Human
ercc1 colorectal cancer Genetic abnormalities have been found to be useful surrogate markers for response, particularly in colorectal cancer: thymidylate synthase mRNA and ERCC1 mRNA levels. 11301850 Human
ercc1 human prostate carcinoma MAPK dependence of DNA damage repair: ionizing radiation and the induction of expression of the DNA repair genes XRCC1 and ERCC1 in DU145 human prostate carcinoma cells in a MEK1/2 dependent fashion. 11682011 Human
ercc1 du145 human prostate cancer MATERIALS AND METHODS: The expression of ERCC1 and XRCC1 was examined in DU145 human prostate cancer cells following exposure to ionizing radiation. 11682011 Human
ercc1 xeroderma pigmentosum Perhaps for this reason, ERCC1 knockout mice are not a model for the human NER deficiency disorder, xeroderma pigmentosum. 11713303 Human
ercc1 colorectal cancer ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. 11731512 Human
ercc1 metastatic colorectal cancer PURPOSE: To test the hypotheses of whether the relative mRNA expression of the thymidylate synthase (TS) gene and the excision cross-complementing (ERCC1) gene are associated with response to and survival of fluorouracil (5-FU)/oxaliplatin chemotherapy in 11731512 Human
ercc1 paraffin-embedded tumor All patients were evaluated for eligibility for a compassionate 5-FU/oxaliplatin protocol. cDNA was derived from paraffin-embedded tumor specimens to determine TS and ERCC1 mRNA expression relative to the internal reference gene beta-actin using fluoresce 11731512 Human
ercc1 tumors RESULTS: The median TS gene expression level from 50 metastasized tumors was 3.4 x 10(-3) (minimum expression, 0.18 x 10(-3);maximum expression, 11.5 x 10(-3)), and the median ERCC1 gene expression level was 2.53 x 10(-3) (minimum, 0.0; maximum, 14.61 x 1 11731512 Human
ercc1 metastatic colorectal cancer CONCLUSION: These data suggest that intratumoral ERCC1 mRNA and TS mRNA expression levels are independent predictive markers of survival for 5-FU and oxaliplatin combination chemotherapy in 5-FU-resistant metastatic colorectal cancer. 11731512 Human
ercc1 human ovarian cancer Human ovarian cancer cells and tissues were examined for the presence or absence of a 42-bp splicing variant of ERCC1 gene, and for a possible functional role of this 42-bp sequence. 11753647 Human
ercc1 ovarian cancer Loss of this 42-bp sequence was associated with increased ERCC1 mRNA expression, in an assessment of 121 ovarian cancer specimens (p2<10(-6)). 11753647 Human
ercc-1 human ovarian cancer Lactacystin enhances cisplatin sensitivity in resistant human ovarian cancer cell lines via inhibition of DNA repair and ERCC-1 expression. 11936875 Human
ercc1 human ovarian carcinoma Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. 10675489 Human
ercc1 human ovarian carcinoma We studied two human ovarian carcinoma cell lines for cisplatin resistance, which differed with respect to ERCC1. 10675489 Human
ercc1 human ovarian cancer These data suggest the possibility that this specific ERCC1 polymorphism, may be associated with reduced DNA repair capacity in human ovarian cancer cells. 10675489 Human
ercc1 human colon tumor Expression of ERCC1 antisense RNA abrogates gemicitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair. 10741696 Human
ercc1 human ovarian cancer Absence of evidence for allelic loss or allelic gain for ERCC1 or for XPD in human ovarian cancer cells and tissues. 10738106 Human
ercc1 human ovarian cancer We have previously reported on mRNA expression of ERCC1, XPA and XPD in human ovarian cancer cells and tissues. 10738106 Human
ercc1 malignant glioma Alterations in gene copy number for ERCC1 and/or XPD have been reported to occur in malignant glioma specimens. 10738106 Human
ercc1 ovarian cancer Genomic DNA was also extracted from ovarian cancer specimens taken from 22 patients and assessed for evidence of allelic loss and/or allelic gain for ERCC1 and XPD. 10738106 Human
ercc-1 human ovarian cancer Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells. 10810335 Human
ercc-1 human ovarian cancer The present study was therefore designed to evaluate the relationship between the expression of ERCC-1 and the repair of cisplatin-induced DNA adducts in human ovarian cancer cells in vitro. 10810335 Human
ercc-1 ovarian tumor Furthermore, the repair of cisplatin-DNA adducts in MCAS cells, as measured by atomic absorption spectrometry, is also nearly two-fold less than that in A2780/CP70 cells, indicating a strong association between the level of ERCC-1 expression and the activ 10810335 Human
ercc-1 tumor These results suggest that ERCC-1 may be a useful marker to monitor the repair of platinum-DNA damage in tumor cells, and further highlight that potential pharmacological approaches which specifically inhibit ERCC-1 expression may increase cellular sensit 10810335 Human
ercc1 lung cancer In a pilot case-control study, we measured the relative expression levels of five NER genes [ERCC1, XPB/ERCC3, XPG/ERCC5, CSB/ERCC6 and XPC (ERCC, excision repair cross-complementing; CSB, Cockayne's syndrome complementary group B)] in phytohemagglut 10910954 Human
ercc1 glioma Association of an ERCC1 polymorphism with adult-onset glioma. 10952103 Human
ercc1 human tumors Because the ERCC1 protein is essential for nucleotide excision repair and influences genomic instability, polymorphisms in ERCC1 may play a role in human tumors. 10952103 Human
ercc1 glioma We determined the presence of the A versus C polymorphism at nucleotide 8092 of ERCC1 using a single-strand conformational polymorphism assay and DNA sequencing in adults with glioma and controls from a population-based study. 10952103 Human
ercc1 brain tumors This is the first study to report a significant association of a polymorphism in ERCC1 with the risk of brain tumors. 10952103 Human
ercc1 tumor Included in this assessment are ERCC1, XPB, CSB, and XPA, studied in 28 ovarian cancer tumor tissue specimens. 10948350 Human
ercc1 ovarian cancer Included in this assessment are ERCC1, XPB, CSB, and XPA, studied in 28 ovarian cancer tumor tissue specimens. 10948350 Human
ercc1 tumor ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells. 11008208 Human
ercc1 cervical cancer We investigated whether high pre-treatment mRNA levels of the ERCC1 nucleotide excision repair gene are predictive of cisplatin resistance in early-passage human cervical cancer cells, as they are in several other tumor types. 11008208 Human
ercc1 cervical carcinoma Expression of the ERCC1 gene at the mRNA and protein levels was established by Northern and Western blotting, respectively, in a panel of single-cell-derived cervical carcinoma cell lines that exhibited a wide range of inherent sensitivity to cisplatin. 11008208 Human
ercc1 tumors Nonetheless, pre-treatment ERCC1 mRNA levels may be a useful molecular marker for identifying cervical tumors likely to be refractory to cisplatin, and further investigation in clinical biopsy material is warranted. 11008208 Human
ercc1 tumors Since these platinum-resistant tumors also show higher mRNA levels of ERCC1 and XPA, platinum resistance appears to be associated with concurrent up-regulation of four genes (XPA, ERCC1, XPB, and CSB). 11077043 Human
ercc-1 ovarian tumor Proteasome inhibition suppresses cisplatin-dependent ERCC-1 mRNA expression in human ovarian tumor cells. 11589365 Human
ercc-1 ovarian cancer These results suggest that the effect of proteasome inhibition on cisplatin cytotoxicity, DNA platination, and DNA repair of cisplatin adducts in ovarian cancer cells may be through down-regulating ERCC-1 expression. 11589365 Human
ercc1 tumor Because studies with rodent cell lines indicate that defects in certain DNA repair genes, including ERCC1, can greatly influence cellular OERs, and because several such repair genes, including ERCC1, localize to a region of chromosome 19q that is close to 14528093 Human
ercc1 glioma Because studies with rodent cell lines indicate that defects in certain DNA repair genes, including ERCC1, can greatly influence cellular OERs, and because several such repair genes, including ERCC1, localize to a region of chromosome 19q that is close to 14528093 Human
ercc-1 human ovarian carcinoma Modulation of excision repair cross complementation group 1 (ERCC-1) mRNA expression by pharmacological agents in human ovarian carcinoma cells. 9933022 Human
ercc-1 human ovarian carcinoma We therefore began to assess the influence of various pharmacological agents on the induction of ERCC-1 mRNA in A2780/CP70 human ovarian carcinoma cells. 9933022 Human
ercc1 cancer The generation of this series of mouse mutants allows in vivo investigation of some intriguing questions that have puzzled the field, such as the paradoxical absence of cancer development in TTD and CS despite their NER deficiencies, and the role of the E 10214917 Human
ercc-1 ovarian tumor Phorbol ester exposure activates an AP-1-mediated increase in ERCC-1 messenger RNA expression in human ovarian tumor cells. 10228559 Human
ercc-1 human ovarian carcinoma We therefore investigated the effect of the phorbol ester 12-O-tetradecanoyl-phorbol-13-acetate (TPA) on the expression of the ERCC-1 gene in A2780/CP70 human ovarian carcinoma cells. 10228559 Human
ercc-1 human ovarian cancer These data suggest that AP-1 may contribute to the upregulation of ERCC-1 in response to TPA in human ovarian cancer cells. 10228559 Human
ercc1 breast cancer Using these methods, we quantified mRNA expression levels of deoxycytidine kinase (dCK), deoxycytidylate deaminase (dCDA), the M1 and M2 subunits of ribonucleotide reductase (RRM1, RRM2), and excision cross complementation group 1 (ERCC1) in 35 human &quo 12938148 Human
ercc1 human breast cancer This reproducible, highly sensitive real-time RT-PCR method for the detection and quantification of the mRNAs for dCK, dCDA, RRM1, RRM2, and ERCC1 in human breast cancer biopsies appears to be more informative and less time-consuming than either classical 12938148 Human
ercc1 gastric cancer ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. 9440758 Human
ercc1 tumors PATIENTS AND METHODS: Patients had intact, untreated, primary gastric adenocarcinoma cancer and were evaluated for eligibility on a preoperative cisplatin infusion-5-FU protocol. cDNA, derived from primary gastric tumors before chemotherapy, was used to d 9440758 Human
ercc1 primary gastric cancers RESULTS: The median ERCC1 mRNA level from 38 primary gastric cancers (33 assessable for response) was 5.8 x 10(-3) (range, 1.8 x 10(-3) to 19.5 x 10(-3)). 9440758 Human
ercc1 gastric adenocarcinoma CONCLUSION: Considered separately, either ERCC1 or TS mRNA levels in a primary gastric adenocarcinoma has a statistically significant relationship to response. 9440758 Human
ercc1 xp-f The XP-FR2 cells expressed high level of XPF protein as well as ERCC1 protein, although their parental XP-F cells expressed extremely low level of both proteins. 9472693 Human
ercc-1 human ovarian carcinoma Effect of interleukin-1 alpha and tumour necrosis factor-alpha on cisplatin-induced ERCC-1 mRNA expression in a human ovarian carcinoma cell line. 9703867 Human
ercc-1 human ovarian cancer Enhanced expression of the human excision repair enzyme ERCC-1 is associated with cellular and clinical resistance to cisplatin in human ovarian cancer. 9703867 Human
ercc-1 human ovarian carcinoma We therefore began to examine the effect of some cisplatin resistance modulators on cisplatin-induced ERCC-1 mRNA expression in the human ovarian carcinoma cell line, A2780/CP70. 9703867 Human
ercc-1 ovarian tumour These findings suggest that the enhancement effect of some agents on cisplatin sensitivity in ovarian tumour cells may be through downregulating ERCC-1 expression. 9703867 Human
ercc-1 human ovarian cancer Cisplatin induction of ERCC-1 mRNA expression in A2780/CP70 human ovarian cancer cells. 9722577 Human
ercc-1 human ovarian cancer In response to a 1-h cisplatin exposure, A2780/CP70 human ovarian cancer cells showed a 6-fold increase in steady-state level of ERCC-1 mRNA. 9722577 Human
ercc1 xp-f All XP-F patients examined demonstrate reduced levels of XPF and ERCC1 protein, suggesting that proper complex formation is required for stability of the two proteins. 9722633 Human
ercc1 xp-f A mutation from an XP-F patient that alters the ERCC1-binding domain in XPF indeed affects complex formation with ERCC1. 9722633 Human
ercc-1 human ovarian carcinoma Cisplatin and phorbol ester independently induce ERCC-1 protein in human ovarian carcinoma cells. 9772291 Human
ercc-1 human ovarian cancer We therefore carried out this study to investigate the effect of cisplatin on ERCC-1 protein expression in A2780/CP70 human ovarian cancer cells. 9772291 Human
ercc1 acute mixed-lineage leukaemia Blasts from one patient with acute mixed lineage leukaemia revealed an abnormally migrated product of the ERCC1 gene by RT-PCR. 9827920 Human
ercc1 childhood leukaemia This is the first report describing a mutation at the ERCC1 gene in acute childhood leukaemia. 9827920 Human
ercc1 human tumor Alternative splicing of ERCC1 and cisplatin-DNA adduct repair in human tumor cell lines. 9852275 Human
ercc1 xeroderma pigmentosum Sensitivity of group F xeroderma pigmentosum cells to UV and mitomycin C relative to levels of XPF and ERCC1 overexpression. 9862190 Human
ercc1 xp-f We transfected XP-F cells with the plasmids expressing XPF or ERCC1 and examined levels of both proteins in the cells. 9862190 Human
ercc1 xp-f Although XP-F cells are sensitive to UV and mitomycin C (MMC), cells overexpressing XPF expressed ERCC1 as well and resistance to UV and MMC was restored to the normal level. 9862190 Human
ercc1 xp-f Even though a high level of ERCC1, which has been presumed to be a catalytic subunit of the endonuclease, is stably present in XP-F cells, ERCC1 protein alone cannot carry out excision repair completely. 9862190 Human
ercc1 human gastric cancer Data exist in human ovarian cancer and in human gastric cancer that ERCC1 may be a useful marker for clinical drug resistance when platinum-based systemic chemotherapy is utilized. 9861196 Human
ercc1 human ovarian cancer Data exist in human ovarian cancer and in human gastric cancer that ERCC1 may be a useful marker for clinical drug resistance when platinum-based systemic chemotherapy is utilized. 9861196 Human
ercc1 human ovarian cancer Although the data suggest that the relative ERCC1 mRNA level may be a good marker for NER activity in human ovarian cancer, it is unclear whether expression of this gene has any relationship to other pathways of DNA repair. 9861196 Human
ercc1 cancer In this study, the mRNA levels of the different genes involved in NER (ERCC1, XPA, XPB, XPC, XPD, XPF) were examined in a panel of eight different human cancer cell lines, together with the overall DNA repair capacity using a host cell reactivation assay 9893669 Human
ercc1 xeroderma pigmentosum A low content of ERCC1 and a 120 kDa protein is a frequent feature of group F xeroderma pigmentosum fibroblast cells. 9025096 Human
ercc1 xp-f The amount of ERCC1 protein expressed in five different XP-F cell strains was 1/ 5-1/34 of that of the protein in normal and XP cell strains representing other complementation groups. 9025096 Human
ercc1 xp-f A 120 kDa protein was co-immunoprecipitated with ERCC1 by the anti-ERCC1 antibody, and the amount of the 120 kDa protein in XP-F cell strains was 1/5-1/8 of that of the protein in normal and XP cell strains representing other complementation groups. 9025096 Human
ercc1 xp-f These results demonstrate that a low level of ERCC1 and the 120 kDa protein is a frequent feature of XP-F cell extracts and that a lower amount of a complex between these proteins occurs in XP-F cells than in normal cells. 9025096 Human
ercc1 brain tumors We previously reported that abnormalities of mRNA expression of ERCC1 and ERCC2 may be characteristic of epithelial ovarian carcinoma and brain tumors. 9234918 Human
ercc1 epithelial ovarian carcinoma We previously reported that abnormalities of mRNA expression of ERCC1 and ERCC2 may be characteristic of epithelial ovarian carcinoma and brain tumors. 9234918 Human
ercc1 squamous carcinoma Inhibition by 5-fluorouracil of ERCC1 and gamma-glutamylcysteine synthetase messenger RNA expression in a cisplatin-resistant HST-1 human squamous carcinoma cell line. 9268987 Human
ercc1 ovarian cancer Therefore, overexpression of ERCC1 and other NER enzymes during ovarian cancer chemotherapy with cisplatin appears to be implicated in the formation of cellular and clinical drug resistance. 12915808 Human
ercc1 human ovarian cancer A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues. 9360634 Human
ercc1 tumor A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues. 9360634 Human
ercc1 human ovarian cancer We studied the DNA sequence of the entire coding region of ERCC1 gene, in five cell lines established from human ovarian cancer (A2780, A2780/CP70, MCAS, OVCAR-3, SK-OV-3), 29 human ovarian cancer tumor tissue specimens, one human T-lymphocyte cell line ( 9360634 Human
ercc1 tumor We studied the DNA sequence of the entire coding region of ERCC1 gene, in five cell lines established from human ovarian cancer (A2780, A2780/CP70, MCAS, OVCAR-3, SK-OV-3), 29 human ovarian cancer tumor tissue specimens, one human T-lymphocyte cell line ( 9360634 Human
ercc1 platinum-resistant ovarian cancer Our data suggest that this alteration at codon 118 within the ERCC1 gene, may exist in platinum-sensitive and platinum-resistant ovarian cancer tissues. 9360634 Human
ercc1 chronic lymphocytic leukemia Levels of DNA cisplatin adducts in peripheral blood and buccal mucosa cells predict chemotherapy response, and high ERCC1 mRNA levels have been related to chemoresistance in ovarian cancer and in malignant lymphocytes from chronic lymphocytic leukemia. 12867068 Human
ercc1 ovarian cancer Levels of DNA cisplatin adducts in peripheral blood and buccal mucosa cells predict chemotherapy response, and high ERCC1 mRNA levels have been related to chemoresistance in ovarian cancer and in malignant lymphocytes from chronic lymphocytic leukemia. 12867068 Human
ercc1 xeroderma pigmentosum Subsequently Xpa and Xpc knockouts have proved to be good models for the human NER deficiency disease, xeroderma pigmentosum, leading to speculation that the recombination, rather than the NER deficit is the key to the Ercc1 knockout phenotype. 12466203 Human
ercc1 xeroderma pigmentosum ERCC1 is not associated with a defect in any of the known human NER disorders: xeroderma pigmentosum, Cockayne's syndrome or trichothiodystrophy. 7596355 Human
ercc1 non-small cell lung cancer Overexpression of ERCC1 correlates with poor survival in gemcitabine/cisplatin-treated non-small cell lung cancer patients. 12917817 Human
ercc1 human tumor At the preclinical level, ERCC1 and XPD mRNA expression correlate with each other, and overexpression of XPD causes selective cisplatin resistance in human tumor cell lines. 12917817 Human
ercc-1 xeroderma pigmentosum The cloned human DNA excision repair gene ERCC-1 fails to correct xeroderma pigmentosum complementation groups A through I. 2918869 Human
ercc-1 xeroderma pigmentosum (xp) We have investigated whether ERCC-1 is the mutated gene in cell lines from xeroderma pigmentosum (XP) complementation groups A through I by analyzing the endogenous gene in XP cells and by introduction of the gene followed by repair assays. 2918869 Human
ercc1 tumors Three tumors (all lower grade) showed concurrent allelic loss of ERCC1 and ERCC2. 8583241 Human
ercc1 glial tumors Abnormalities in copy number of ERCC1 and ERCC2 are common in glial tumors. 8583241 Human
ercc1 ovarian cancer Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. 8040325 Human
ercc1 malignant ovarian cancer We therefore assessed mRNA levels of ERCC1 and XPAC in malignant ovarian cancer tissues from 28 patients that were harvested before the administration of platinum-based chemotherapy. 8040325 Human
ercc1 cancer Cancer tissues from patients whose tumors were clinically resistant to therapy (n = 13) showed greater levels of total ERCC1 mRNA (P = 0.059), full length transcript of ERCC1 mRNA (P = 0.026), and XPAC mRNA (P = 0.011), as compared with tumor tissues from 8040325 Human
ercc1 tumor Cancer tissues from patients whose tumors were clinically resistant to therapy (n = 13) showed greater levels of total ERCC1 mRNA (P = 0.059), full length transcript of ERCC1 mRNA (P = 0.026), and XPAC mRNA (P = 0.011), as compared with tumor tissues from 8040325 Human
ercc1 tumors Cancer tissues from patients whose tumors were clinically resistant to therapy (n = 13) showed greater levels of total ERCC1 mRNA (P = 0.059), full length transcript of ERCC1 mRNA (P = 0.026), and XPAC mRNA (P = 0.011), as compared with tumor tissues from 8040325 Human
ercc1 ovarian cancer These data suggest greater activity of the DNA excision repair genes ERCC1 and XPAC in ovarian cancer tissues of patients clinically resistant to platinum compounds. 8040325 Human
ercc1 ovarian cancer These data also indicate highly variable splicing of ERCC1 mRNA in ovarian cancer tissues in vivo, whether or not such tissues are sensitive to platinum-based therapy. 8040325 Human
ercc1 tumors The requirement for ERCC2 and ERCC3, combined with the finding that ERCC1 but not ERCC2 is upregulated in drug-resistant tumors, may explain the efficacy of illudins against drug-resistant tumors. 8053936 Human
ercc1 prostate carcinoma Epidermal growth factor and ionizing radiation up-regulate the DNA repair genes XRCC1 and ERCC1 in DU145 and LNCaP prostate carcinoma through MAPK signaling. 12643788 Human
ercc1 prostate carcinoma This work examined the importance of radiation-induced and ligand-induced EGFR-ERK signaling for the regulation of DNA repair proteins XRCC1 and ERCC1 in prostate carcinoma cells, DU145 (TP53(mut)), displaying EGFR-TGFA-dependent autocrine growth and high 12643788 Human
ercc1 teratoma Whilst the ovarian carcinoma cells inherently expressed markedly higher levels (30- to 50-fold) of the excision repair gene ERCC1 than the teratoma cells, only the teratoma DXR10 subline showed an increased level of expression of ERCC1 mRNA relative to th 7923602 Human
ercc1 ovarian carcinoma Whilst the ovarian carcinoma cells inherently expressed markedly higher levels (30- to 50-fold) of the excision repair gene ERCC1 than the teratoma cells, only the teratoma DXR10 subline showed an increased level of expression of ERCC1 mRNA relative to th 7923602 Human
ercc1 cancer The patterns of expression of 3 human DNA-repair genes (ERCC1, ERCC2, ERCC6) were assessed in 52 bone-marrow specimens obtained from cancer patients prepared for autologous bone-marrow transplantation. 7678143 Human
ercc-1 ovarian carcinoma Previous studies of ERCC-1 gene expression levels in chronic lymphocytic leukemia and ovarian carcinoma tumor specimens indicated that increased gene expression may correlate with a lack of response to the alkylating agents, melphalan, and cis-diamminedic 8324733 Human
ercc-1 chronic lymphocytic leukemia Previous studies of ERCC-1 gene expression levels in chronic lymphocytic leukemia and ovarian carcinoma tumor specimens indicated that increased gene expression may correlate with a lack of response to the alkylating agents, melphalan, and cis-diamminedic 8324733 Human
ercc-1 tumor Previous studies of ERCC-1 gene expression levels in chronic lymphocytic leukemia and ovarian carcinoma tumor specimens indicated that increased gene expression may correlate with a lack of response to the alkylating agents, melphalan, and cis-diamminedic 8324733 Human
ercc1 ovarian cancer ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. 1433335 Human
ercc1 tumor Relative expression levels were determined by comparing each tumor sample with a Chinese hamster ovary cell line that had a stable transfection of the human ERCC1 gene. 1433335 Human
ercc1 tumor RESULTS: Patients who were clinically resistant to platinum-based therapy had a 2.6-fold higher expression level of ERCC1 in their tumor tissue than did patients who responded to that therapy (P = .015). 1433335 Human
ercc1 human tumor CONCLUSION: We conclude that ERCC1 expression levels in human tumor tissue may have a role in clinical resistance to platinum compounds. 1433335 Human
ercc-1 ovarian carcinoma Treatment of the ovarian carcinoma cells with SU5416 was also associated with a reduced expression of ERCC-1 protein and c-jun mRNA, as well as a decrease in c-Jun and JNK activities. 12785726 Human
ercc1 ovarian cancer Levels of DNA cisplatin adducts in peripheral blood and buccal mucosa cells predict chemotherapy response, and high ERCC1 mRNA levels have been related to chemoresistance in ovarian cancer and in malignant lymphocytes from chronic lymphocytic leukemia. 14668933 Human
ercc1 chronic lymphocytic leukemia Levels of DNA cisplatin adducts in peripheral blood and buccal mucosa cells predict chemotherapy response, and high ERCC1 mRNA levels have been related to chemoresistance in ovarian cancer and in malignant lymphocytes from chronic lymphocytic leukemia. 14668933 Human
ercc1 non-small cell lung cancer Overexpression of ERCC1 correlates with poor survival gemcitabine/cisplatin-treated non-small cell lung cancer patients. 14668933 Human
ercc1 human tumor At the preclinical level, ERCC1 and XPD mRNA expression correlate with each other, and overexpression of XPD causes selective cisplatin resistance in human tumor cell lines. 14668933 Human
ercc1 tumor Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines. 15095299 Human
ercc1 tumor We previously investigated 2 testis tumor cell lines with a low capacity to remove cisplatin-induced DNA damage and found that they had low levels of the DNA nucleotide excision repair proteins XPA, ERCC1 and XPF. 15095299 Human
ercc1 cancers To determine whether low levels of XPA, ERCC1 and XPF proteins are characteristic of testis tumor cell lines, we investigated 35 cell lines derived from cancers to determine whether groups of cell lines from diverse tissue origins differ from one another 15095299 Human
ercc1 tumor To determine whether low levels of XPA, ERCC1 and XPF proteins are characteristic of testis tumor cell lines, we investigated 35 cell lines derived from cancers to determine whether groups of cell lines from diverse tissue origins differ from one another 15095299 Human
ercc1 tumor Only the 6 testis tumor cell lines showed significantly lower mean levels of XPA (p = 0.001), XPF (p = 0.001) and ERCC1 (p = 0.004) proteins from the other groups. 15095299 Human
ercc1 colorectal cancer We have compared the frequency of polymorphisms in the NER genes, XPD, XPF, XPG, ERCC1; in the BER gene, XRCC1; and in the RR gene, XRCC3; in colorectal cancer patients and in a control group. 12865926 Human
ercc-1 non-small cell lung cancer [Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer] BACKGROUND & OBJECTIVE: The molecular predictor for cisplatin sensitivity in advanced non-small cell lung 15248926 Human
ercc-1 non-small cell lung cancer The purpose of this study was to evaluate the relationship of the cisplatin sensitivity/prognosis with the expression of excision repair cross complement-1 (ERCC-1), metallothionein (MT), and p53 in the paraffin-embedded tissue of advanced non-small cell 15248926 Human
ercc-1 nsclc The purpose of this study was to evaluate the relationship of the cisplatin sensitivity/prognosis with the expression of excision repair cross complement-1 (ERCC-1), metallothionein (MT), and p53 in the paraffin-embedded tissue of advanced non-small cell 15248926 Human
ercc-1 tumor At the same time, the tumor samples were collected and the expression of ERCC-1, MT, and p53 in the tumor samples were examined by immunohistochemical method. 15248926 Human
ercc-1 nsclc CONCLUSION: Whether over-expression of ERCC-1 and MT can be used as a molecular marker of cisplatin resistance in advanced NSCLC patients need further study. 15248926 Human
ercc1 cll Northern blot analysis of ERCC1 gene (a putative DNA repair enzyme involved in nucleotide excision repair) expression in lymphocytes from patients with CLL revealed multiple gene transcripts (1.1, 3.4, and 3.8 kilobases). 2005641 Human
ercc1 cll These results indicate that increased expression of ERCC1 and increased activity of 3-methyladenine-DNA glycosylase occur with the development of resistance to the nitrogen mustards in patients with CLL, suggesting a role for enhanced DNA repair in this p 2005641 Human
ercc1 gliomas To bracket the putative tumor suppressor gene further, we have studied this region in 55 gliomas, using loss of heterozygosity studies for 11 well mapped, highly informative microsatellite polymorphisms that cover this area: D19S178; BCL3; APOC2; ERCC1; D 8062276 Human
ercc1 gliomas Genomic copy number changes of DNA repair genes ERCC1 and ERCC2 in human gliomas. 8583241 Human
ercc1 brain tumor ERCC1 and ERCC2. Radiodensitometry was used to assess gene copy number in samples obtained from brain tumor specimens from 24 patients. 8583241 Human
ercc1 gastric tumors PATIENTS AND METHODS: Patients had intact, untreated, primary gastric adenocarcinoma cancer and were evaluated for eligibility on a preoperative cisplatin infusion-5-FU protocol. cDNA, derived from primary gastric tumors before chemotherapy, was used to d 9440758 Human
ercc1 cervical tumor ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells. 11008208 Human
ercc1 other tumor We investigated whether high pre-treatment mRNA levels of the ERCC1 nucleotide excision repair gene are predictive of cisplatin resistance in early-passage human cervical cancer cells, as they are in several other tumor types. 11008208 Human
ercc1 cervical tumors Nonetheless, pre-treatment ERCC1 mRNA levels may be a useful molecular marker for identifying cervical tumors likely to be refractory to cisplatin, and further investigation in clinical biopsy material is warranted. 11008208 Human
ercc1 necrosis ERCC1 and ERCC3 mutants showed a higher frequency of apoptosis and, to a lesser degree, necrosis compared to repair proficient cells. 11516928 Human
ercc1 nsclc We investigated whether ERCC1 mRNA expression levels were associated with clinical outcomes after treatment with a combination Gem/CDDP regimen for patients with advanced stage non-small cell lung cancer (NSCLC). 12114432 Human
ercc1 nsclc EXPERIMENTAL DESIGN: Response and survival were correlated with the level of ERCC1 expression in 56 patients with advanced (stage IIIb or IV) NSCLC treated as part of a multicenter randomized trial with Gem 1250 mg/m(2) days 1 and 8 plus CDDP 100 mg/m(2) 12114432 Human
ercc1 nsclc CONCLUSIONS: These data suggest that ERCC1 expression is a predictive factor for survival after CDDP/Gem therapy in advanced NSCLC. 12114432 Human
ercc1 nsclc Prospective studies of ERCC1 as a predictive marker for activity of CDDP-based regimens in NSCLC are warranted. 12114432 Human
ercc1 nsclc Overexpression of ERCC1 correlates with poor survival in gemcitabine/cisplatin-treated NSCLC patients. 12867068 Human
ercc1 lung cancer CONCLUSION: Antisense ERCC1 RNA decreased the repair capability for damaged DNA in lung cancer cells induced by benzo[a]pyrene. 12880561 Human
ercc1 nsclc Recently, baseline ERCC1 mRNA overexpression has been related to poor response and survival in cisplatin-treated NSCLC patients. 12915808 Human
ercc1 non-small-cell lung cancer Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. 15140544 Human
ercc1 non-small-cell lung cancer Therefore, we suggest that the C/C genotype in codon 118 of ERCC1 is a surrogate marker for predicting better survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. 15140544 Human
ercc1 locally advanced esophageal cancer We examined the potential of quantitative ERCC1 mRNA expression to predict minor or major histopathological response to neoadjuvant radiochemotherapy (cisplatin, 5-fluorouracil, and 36 Gy of radiation) followed by transthoracic en bloc esophagectomy in pa 15173087 Human
ercc1 locally advanced esophageal cancer CONCLUSIONS: Relative expression levels of ERCC1 mRNA determined by quantitative real-time reverse transcriptase-PCR appear highly specific to predict minor response to our neoadjuvant radiochemotherapy protocol in patients with locally advanced esophagea 15173087 Human
ercc1 tumor ERCC1, RRM1, and XPD are involved in the nucleotide excision repair pathways, and tumor up-regulation of these genes leads to chemotherapy failure. 15217961 Human
ercc1 non-small cell lung cancer In the present study, we have examined the potential correlation and predictive value of ERCC1, RRM1, and XPD mRNA expression in resected specimens from 67 stage IIB, IIIA, and IIIB non-small cell lung cancer patients treated with neoadjuvant gemcitabine/ 15217961 Human
ercc1 stage iv nsclc We assessed whether single nucleotide polymorphisms (SNPs) in ERCC1, XPD, RRM1 and MDR1, and ERCC1 mRNA expression, predicted survival in docetaxel-cisplatin-treated stage IV NSCLC patients. 15277258 Human
ercc1 nsclc PATIENTS AND METHODS: Using the TaqMan 5' nuclease assay, we examined ERCC1 118, XPD 751 and 312, RRM1 -37C/A, and MDR1 C3435T SNPs in peripheral blood lymphocytes (PBLs) obtained from 62 docetaxel-cisplatin-treated advanced NSCLC patients. 15277258 Human
ercc1 cancers Increased ERCC1 mRNA levels are related directly to platinum resistance in various cancers. 15297394 Human
ercc1 non-small cell lung cancer We examined the association between two polymorphisms of ERCC1, codon 118 C/T and C8092A, which are associated with altered ERCC1 mRNA levels and mRNA stability, and overall survival (OS) in 128 advanced non-small cell lung cancer patients treated with pl 15297394 Human
ercc1 non-small cell lung cancer In conclusion, the ERCC1 C8092A polymorphism may be a useful predictor of OS in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. 15297394 Human
ercc1 solid tumor Comparison of the IC50 values for irofulven, cisplatin, and ecteinascidin 743 with the expression levels of ERCC1, XPD, and XPG genes in different solid tumor cell lines shows no correlation between the expression levels of any of the three nucleotide exc 15328203 Human
ercc1 ovarian cancer This 42-bp segment seems to possess a regulatory function in ERCC1 expression and representing the level of clinical response to platinum-treatment in ovarian cancer patients. 15375562 Human
ercc1 ovarian cancer Northern blot analysis and RNase protection assay provide evidence that the 42-bp deletion occurs at RNA level of ERCC1 5'-UTR in both ovarian cancer cell lines and ovarian cancer tissues. 15375562 Human
ercc1 ovarian cancer Luciferase assay suggests that this gene fragment possesses a regulatory function as an enhancer of ERCC1 gene expression in ovarian cancer cells. 15375562 Human
ercc1 ovarian cancer We conclude that the 42-bp sequence within the 5'-UTR influences the expression of ERCC1 and hence can influence response to cisplatin in ovarian cancer therapy. 15375562 Human
ercc1 cancer In this report we reviewed the pathway leading to ERCC1 gene transcription and translation in cancer cells when exposed to cisplatin. 15547660 Human
ercc1 cancers We summarized data from different cancer cell lines and human cancers showing that the high level of ERCC1-mRNA and/or ERCC1 protein is associated with resistance to platinum compounds with direct impact on cancer patient survival and finally we analyzed 15547660 Human
ercc1 cancer We summarized data from different cancer cell lines and human cancers showing that the high level of ERCC1-mRNA and/or ERCC1 protein is associated with resistance to platinum compounds with direct impact on cancer patient survival and finally we analyzed 15547660 Human
ercc1 cancer Small interfering RNA-induced suppression of ERCC1 enhances sensitivity of human cancer cells to cisplatin. 15629453 Human
ercc1 tumor The level of excision repair cross-complementing 1 (ERCC1) gene expression, which is important in the repair of the cisplatin-DNA adducts, is reported to be related to the level of cisplatin resistance in tumor cells. 15629453 Human
ercc1 cancer This study is the first to demonstrate the feasibility of utilizing ERCC1 siRNAs to specifically reduce the ERCC1 expression level in human cancer cells and provides direct evidence for the potential use of ERCC1 siRNA as a chemotherapy-sensitizing agent. 15629453 Human
ercc1 lung cancer Gene-Smoking Interaction Associations for the ERCC1 Polymorphisms in the Risk of Lung Cancer. 15734977 Human
ercc1 cancers Excision repair cross-complementing group 1 (ERCC1) is the lead enzyme in the nucleotide excision repair process, and low expression of ERCC1 mRNA levels has been associated with higher risk of cancers. 15734977 Human
ercc1 lung cancer We examined the association between two polymorphisms of ERCC1, 8092C > A (rs3212986) and 19007T > C (codon 118, rs11615), which are associated with altered ERCC1 mRNA stability and mRNA levels, in 1,752 Caucasian lung cancer patients and 1,358 controls. 15734977 Human
ercc1 lung cancer There was no overall association between ERCC1 polymorphisms and lung cancer risk, with the adjusted odds ratios (AOR) of 1.26 [95% confidence interval (95% CI), 0.81-1.96] for the 8092C > A polymorphism (A/A versus C/C) and 0.93 (95% CI, 0.67-1.30) for t 15734977 Human
ercc1 lung cancer In conclusion, ERCC1 8092C > A polymorphism may modify the associations between cumulative cigarette smoking and lung cancer risk. 15734977 Human
ercc1 esophageal cancer Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer. 15737843 Human
ercc1 non-small cell lung cancer Polymorphisms in ERCC1 and Grade 3 or 4 Toxicity in Non-Small Cell Lung Cancer Patients. 15746057 Human
ercc1 non-small cell lung cancer CONCLUSIONS: Adjusting for performance status and type of treatment regimen, carrying at least one ERCC1 8092A allele is associated with a >2-fold increase in grade 3 or 4 gastrointestinal toxicity among platinum-treated non-small cell lung cancer patient 15746057 Human
ercc1 non-small cell lung cancer Adjusting covariates were performance status and type of treatment regimen.RESULTS: There was no statistically significant association between either the C8092A or codon 118 polymorphism and overall or hematologic grade 3 or 4 toxicity. 15746057 Human
ercc1 non-small cell lung cancer ERCC1 Expression Is a Predictor of Survival in Resected Patients With Non-small Cell Lung Cancer. 15764785 Human
ercc1 non-small cell lung cancer We therefore evaluated the effect of intratumoral ERCC1 expression on survival in non-small cell lung cancer (NSCLC) patients who underwent surgical resection for cure. 15764785 Human
ercc1 nsclc We therefore evaluated the effect of intratumoral ERCC1 expression on survival in non-small cell lung cancer (NSCLC) patients who underwent surgical resection for cure. 15764785 Human
ercc1 tumor There were no significant correlations between ERCC1 expression in tumor tissue and normal lung. 15764785 Human
ercc1 nsclc CONCLUSIONS: We conclude that resected NSCLC patients with high ERCC1 expression (> 50) have a better survival when compared to patients with low ERCC1 expression (< 50). 15764785 Human
ercc1 nsclc Future adjuvant and neoadjuvant chemotherapy trials in NSCLC could stratify patients according to their ERCC1 expression levels. 15764785 Human
ercc1 cancer Expression of a splicing variant in the 5'-UTR of the human ERCC1 gene is not cancer related. 15688021 Human
ercc1 ovarian tumours One of the mechanisms of resistance of ovarian tumours to cisplatin is increased nucleotide excision repair activity, in particular increased levels of the endonuclease ERCC1. 15688021 Human
ercc1 ovarian cancers Since 30-40% of ovarian cancers develop resistance to cisplatin after treatment and these tumours are usually incurable, ERCC1 expression is potentially useful as a predictive marker for the effectiveness of cisplatin-based chemotherapy. 15688021 Human
ercc1 tumours Since 30-40% of ovarian cancers develop resistance to cisplatin after treatment and these tumours are usually incurable, ERCC1 expression is potentially useful as a predictive marker for the effectiveness of cisplatin-based chemotherapy. 15688021 Human
ercc1 ovarian cancer Using RT-PCR and Northern blotting, we have examined the expression of a 42 bp differentially spliced sequence in exon 1 of the human ERCC1 gene, loss of which has previously been reported to be correlated with higher levels of ERCC1 mRNA in ovarian cance 15688021 Human
ercc1 esophageal cancer High Gene Expression of TS1, GSTP1, and ERCC1 Are Risk Factors for Survival in Patients Treated with Trimodality Therapy for Esophageal Cancer. 15788669 Human
ercc1 esophageal tumor Additionally, the presence of ERCC1 >3.0 or TS1 >6.0 was associated with an approximately 2-fold increase in the risk of cancer recurrence (P = 0.086 and 0.003, respectively).Conclusion: The measurement of relative gene expression of molecular markers ass 15788669 Human
ercc1 cancer Additionally, the presence of ERCC1 >3.0 or TS1 >6.0 was associated with an approximately 2-fold increase in the risk of cancer recurrence (P = 0.086 and 0.003, respectively). 15788669 Human
ercc1 esophageal cancer Additionally, the presence of ERCC1 >3.0 or TS1 >6.0 was associated with an approximately 2-fold increase in the risk of cancer recurrence (P = 0.086 and 0.003, respectively).Conclusion: The measurement of relative gene expression of molecular markers ass 15788669 Human
ercc1 ovarian cancer Preclinical models in an ovarian cancer cell line (A2780) have demonstrated synergistic activity when gemcitabine is added to cisplatin compared with either single agent alone. 15839954 Human
ercc1 cancer Inhibition of specific exonucleases, such as excision repair cross-complementation group 1 (ERCC1), is integral to the platinum-gemcitabine synergy. 15839954 Human
ercc1 basal-cell carcinoma Effect of polymorphisms in XPD, RAI, ASE-1 and ERCC1 on the risk of basal cell carcinoma among Caucasians after age 50. 15936590 Human
ercc1 breast cancer RESULTS: We found that the RAD52 2259 CT or TT, hMLH1 -93 GG, and ERCC1 8092 AA genotypes were associated with breast cancer risk after adjustment for known risk factors [odds ratio (OR), 1.33; 95% confidence interval (95% CI), 1.02-1.75; OR, 1.31; 95% CI 15958648 Human
ercc1 breast cancer CONCLUSION: Our findings suggest that genetic polymorphisms of RAD52, ERCC1, and hMLH1 may be associated with breast cancer risk in Korean women. 15958648 Human
ercc1 testicular cancer We found that neither polymorphisms in several DNA repair genes nor alleles of several polymorphisms in the chromosomal of region 19q13.2-3, encompassing the genes ASE, ERCC1, RAI and XPD, were associated with risk of testicular cancer in Danish patients. 15885892 Human
ercc1 other cancers This is in contrast to other cancers, where we reported strong associations between polymorphisms in ERCC1, ASE and RAI and occurrence of basal cell carcinoma, breast cancer and lung. 15885892 Human
ercc1 breast cancer This is in contrast to other cancers, where we reported strong associations between polymorphisms in ERCC1, ASE and RAI and occurrence of basal cell carcinoma, breast cancer and lung. 15885892 Human
ercc1 basal-cell carcinoma This is in contrast to other cancers, where we reported strong associations between polymorphisms in ERCC1, ASE and RAI and occurrence of basal cell carcinoma, breast cancer and lung. 15885892 Human
ercc1 human hepatocellular carcinoma Overexpression of the two nucleotide excision repair genes ERCC1 and XPC in human hepatocellular carcinoma. 15922480 Human
ercc1 hcc METHODS: Expression of CSA, CSB, XPC, hHR23B, XPA, XPB, ERCC1 and p53 genes was analyzed by quantitative RT-PCR and immunoblotting in 26 HCC and 9 normal livers. 15922480 Human
ercc1 hcc XPA, XPC, hHR23B and ERCC1 mRNA levels were significantly increased (p<0.05) in HCC arising in cirrhotic livers compared to non fibrotic tissue. 15922480 Human
ercc1 tumors Moreover, expression of ERCC1, XPA and XPC mRNA was significantly augmented in HCC, even more in tumors arising in cirrhotic liver. 15922480 Human
ercc1 hcc Moreover, expression of ERCC1, XPA and XPC mRNA was significantly augmented in HCC, even more in tumors arising in cirrhotic liver. 15922480 Human
ercc1 hcc ERCC1, XPC ad XPA mRNA levels were highly correlated in NT and HCC. 15922480 Human
ercc1 hcc XPC and ERCC1 protein levels were also increased in HCC. 15922480 Human
ercc1 cancer CONCLUSIONS: Our findings strongly suggest that overexpression of two key genes involved in the early steps of the NER process, ERCC1 and XPC, is associated with liver fibrogenesis and cancer and could be related to the well recognized resistance of HCC t 15922480 Human
ercc1 hcc CONCLUSIONS: Our findings strongly suggest that overexpression of two key genes involved in the early steps of the NER process, ERCC1 and XPC, is associated with liver fibrogenesis and cancer and could be related to the well recognized resistance of HCC t 15922480 Human
ercc1 lung cancer We studied single nucleotide polymorphisms (SNPs) and their corresponding haplotypes in 6 genes (ERCC1, ERCC2/XPD, ERCC4/XPF, ERCC5/XPG, RAD23B and XPC) involved in NER in a population-based case-control study of lung cancer in Xuan Wei. 15849729 Human
ercc1 advanced colorectal cancer ERCC1 Codon 118 Polymorphism Is a Predictive Factor for the Tumor Response to Oxaliplatin/5-Fluorouracil Combination Chemotherapy in Patients with Advanced Colorectal Cancer. 16144923 Human
ercc1 tumor ERCC1 Codon 118 Polymorphism Is a Predictive Factor for the Tumor Response to Oxaliplatin/5-Fluorouracil Combination Chemotherapy in Patients with Advanced Colorectal Cancer. 16144923 Human
ercc1 metastatic colorectal cancer PURPOSE: The aim of our study was to assess whether the polymorphism of the nucleotide excision repair enzyme, excision repair cross-complementing rodent repair deficiency, complementation group 1 (ERCC1), had an effect on the tumor response in patients t 16144923 Human
ercc1 tumor PURPOSE: The aim of our study was to assess whether the polymorphism of the nucleotide excision repair enzyme, excision repair cross-complementing rodent repair deficiency, complementation group 1 (ERCC1), had an effect on the tumor response in patients t 16144923 Human
ercc1 metastatic colorectal cancer This change results in a decreased ERCC1 gene expression, which impairs repair activity.EXPERIMENTAL DESIGN: Ninety-one patients with a median age of 55.1 years treated for a metastatic colorectal cancer were included in our retrospective study. 16144923 Human
ercc1 metastatic colorectal cancer The ERCC1 polymorphism was analyzed in the normal tissue of all patients.RESULTS: Twenty (22%) were homozygous for AAC codon (C/C genotype), 30 were (33%) homozygous for AAT codon (T/T genotype), and 41 (45%) were heterozygous (C/T genotype). 16144923 Human
ercci bcc The results show a significant association between BCC and the A-allele of a polymorphism in ERCCI exon4 (Odds ratio 12;95% Confidence Interval 1.17-124; p(chi2, two-side) = 0.019) and to a lesser extent with XPD exon6 (p = 0.06). 12645871 Human

< Top >


Download all image files.
Save all PNG files.    Save all PDF files.    Save all PS files.